Biologics company Vericel's Q2 revenue misses expectations

Vericel

31/07/2025 13:20

Overview

Vericel Q2 revenue grows 20% to $63.2 mln, missing analyst expectations

Adjusted EBITDA rises 112% to $13.4 mln, reflecting improved profitability

Company receives FDA IND clearance for Phase 3 MACI Ankle study

Outlook

Vericel reaffirms MACI full-year revenue growth in low 20% range

Company updates Burn Care revenue guidance to $10 mln per qtr for H2 2025

Vericel maintains full-year gross margin guidance of 74%

Company expects adjusted EBITDA margin of 26% for full year

Result Drivers

MACI REVENUE GROWTH - MACI revenue increased by 21% to $53.5 mln, driven by higher implant volumes and sales force expansion

GROSS MARGIN IMPROVEMENT - Gross margin rose more than 400 basis points to 74%, contributing to improved profitability

BURN CARE REVENUE - NexoBrid revenue grew 52% year-over-year, with the highest number of hospital unit orders in June

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$63.24 mln
$64.50 mln (8 Analysts)
Q2 EPS
-$0.01
Q2 Net Income
-$553,000
Q2 Adjusted EBITDA
$13.36 mln
Q2 Gross Margin
74.0%
Q2 Adjusted EBITDA Margin
21.0%
Q2 Gross Profit
$46.61 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Vericel Corp is $58.50, about 30.5% above its July 30 closing price of $40.66

The stock recently traded at 81 times the next 12-month earnings vs. a P/E of 103 three months ago

Press Release: ID:nGNX6Vmgvm

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)